Semax Research
ACTH Fragment Analog Neuropeptide
Research area: cognitive signaling research
Semax is a synthetic heptapeptide analog of the ACTH(4–10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is studied for its activity in cognitive signaling, BDNF (brain-derived neurotrophic factor) expression, and neuroprotective pathway research. It is registered as a pharmaceutical in Russia.
Research Areas
Cognitive Signaling Research
Studies examine Semax's influence on attention, working memory-related neural pathways, and nootropic signaling research. It is registered in Russia for applications including ischemic stroke recovery and cognitive signaling research.
BDNF & Neurotrophin Pathways
Research has reported Semax's influence on BDNF (brain-derived neurotrophic factor), VEGF, and NGF expression in brain tissue, with implications for neuroplasticity and neuroprotective pathway research.
Neuroprotective Signaling
Preclinical studies have investigated Semax in models of ischemia and oxidative neurological stress, examining its potential effects on neuroprotective cellular signaling pathways.
Dopaminergic & Serotonergic Modulation
Research explores Semax's interactions with dopaminergic and serotonergic signaling systems and their relevance to mood and cognitive performance pathway research.
Registered pharmaceutical in Russia; investigational in most other regions. Cognitive signaling research compound.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about Semax?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation